Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 25, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 2,200,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,129.47 pence per share.
- Treasury Holdings: Following cancellation, the Company holds 474,194,158 shares in Treasury, representing 8.95% of total voting rights.
- Shares in Issue: 5,296,168,549 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,200,000 repurchased shares. Consequently, the total number of shares in issue was adjusted to 5,296,168,549. The filing does not provide comparative data against prior periods for operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,296,168,549) for accurate calculation of ownership percentages under Disclosure and Transparency Rules.
- Confirm the Treasury share count (474,194,158) and its impact on total voting rights (8.95%).
- Note that this filing is a transactional report and does not contain operational or financial performance data for the period.